{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:20:00Z","timestamp":1774459200574,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.schres.2024.07.038","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T21:19:07Z","timestamp":1721337547000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Does relapse cause illness progression in first-episode psychosis? A review"],"prefix":"10.1016","volume":"271","author":[{"given":"Kevin P.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Zito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.07.038_bb0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.schres.2015.01.021","article-title":"Minimal evidence that untreated psychosis damages brain structures: a systematic review","volume":"162","author":"Anderson","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/schbul\/sbaa145","article-title":"Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12-year follow-up study of first-episode schizophrenia-Spectrum disorders","volume":"47","author":"Chan","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.07.038_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2024.07.038_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MLR.0b013e318207ed9e","article-title":"Placebo adherence, clinical outcomes, and mortality in the women\u2019s health initiative randomized hormone therapy trials","volume":"49","author":"Curtis","year":"2011","journal-title":"Med. Care"},{"key":"10.1016\/j.schres.2024.07.038_bb0035","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but Normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0040","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/wps.20521","article-title":"Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse","volume":"17","author":"Emsley","year":"2018","journal-title":"World psychiatry : official journal of the World Psychiatric Association (WPA)"},{"key":"10.1016\/j.schres.2024.07.038_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JCP.0b013e31827bfcc1","article-title":"Comparison of treatment response in second-episode versus first-episode schizophrenia","volume":"33","author":"Emsley","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.07.038_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2019.11.025","article-title":"Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia","volume":"225","author":"Emsley","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/02698811221087645","article-title":"The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: a systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms","volume":"36","author":"Fountoulakis","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.07.038_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1192\/bjp.bp.110.081471","article-title":"Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial","volume":"199","author":"Girgis","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","article-title":"A method for tapering antipsychotic treatment that may minimize the risk of relapse","volume":"47","author":"Horowitz","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2024.07.038_bb0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2016.03.026","article-title":"Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis","volume":"174","author":"Hui","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2020.02.007","article-title":"Perspective on medication decisions following remission from first-episode psychosis","volume":"225","author":"Hui","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2019.19030324","article-title":"Lead-time Bias confounds association between duration of untreated psychosis and illness course in schizophrenia","volume":"177","author":"Jonas","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbad112","article-title":"Addressing the evidence to practice gap: what to expect from international antipsychotic dose reduction studies in the tapering anti-psychotics and evaluating recovery consortium","volume":"50","author":"Koops","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.07.038_bb0115","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","article-title":"Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies","volume":"211","author":"Lally","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/1516-4446-2014-1539","article-title":"Determinants of adherence to treatment in first-episode psychosis: a comprehensive review","volume":"37","author":"Leclerc","year":"2015","journal-title":"Brazilian Journal of Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0130","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2215-0366(23)00308-5","article-title":"Antipsychotic dose reduction: unclear benefits but certain risks","volume":"10","author":"Leucht","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0893-133X(95)00200-W","article-title":"Psychobiologic correlates of treatment response in schizophrenia","volume":"14","author":"Lieberman","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.07.038_bb6000","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1017\/S0033291723000429","article-title":"Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort","volume":"53","author":"Liu","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.schres.2021.04.011","article-title":"Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: results from the PAFIP-10 cohort","volume":"232","author":"Mayoral-van Son","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0150","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.schres.2018.02.056","article-title":"Early treatment resistance in a Latin-American cohort of patients with schizophrenia","volume":"199","author":"Mena","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0155","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1017\/S0033291718003811","article-title":"A critical analysis of recent data on the long-term outcome of antipsychotic treatment","volume":"49","author":"Moncrieff","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2019.08.035","article-title":"Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: a systematic review","volume":"225","author":"Moncrieff","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0165","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1017\/S0033291721001872","article-title":"Antipsychotic discontinuation and recovery: chicken or egg?","volume":"53","author":"Pierre","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0170","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1017\/S0033291719001296","article-title":"Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study","volume":"50","author":"Rubio","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0175","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1017\/S0033291713002341","article-title":"Does active psychosis cause neurobiological pathology? A critical review of the neurotoxicity hypothesis","volume":"44","author":"Rund","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.07.038_bb0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/13651501.2014.1002501","article-title":"Towards a pragmatic and operational definition of relapse in schizophrenia: a Delphi consensus approach","volume":"19","author":"San","year":"2015","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.schres.2024.07.038_bb0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","article-title":"Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms","volume":"215","author":"Shimomura","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.07.038_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2215-0366(22)00015-3","article-title":"Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study","volume":"9","author":"Taipale","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0205","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41386-018-0278-3","article-title":"Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia","volume":"44","author":"Takeuchi","year":"2019","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.07.038_bb0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2009.2017","article-title":"Composite end points in randomized trials: there is no free lunch","volume":"303","author":"Tomlinson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2024.07.038_bb0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.07.038_bb0220","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.07.038_bb0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2019.10.057","article-title":"Rethinking the risks and benefits of long-term maintenance in schizophrenia","volume":"225","author":"Zito","year":"2020","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T14:26:29Z","timestamp":1725719189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642400344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":46,"alternative-id":["S092099642400344X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.07.038","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does relapse cause illness progression in first-episode psychosis? A review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}